Department of Gynaecology and Obstetrics, First People's Hospital of Wenling, Wenling, China.
Kaohsiung J Med Sci. 2019 Apr;35(4):222-229. doi: 10.1002/kjm2.12020. Epub 2019 Apr 8.
Research on anticervical cancer is urgently required to enhance clinical outcomes. As a main anticancer drug for cervical carcinoma, cisplatin (CIS) has been used for a lot of years in clinical therapy. However, serious adverse effects including nephrotoxicity and neurotoxicity limit its long-term treatment. Our main goal of this study is to investigate the improvement of Ganoderma lucidum polysaccharides (GPS) on CIS-induced antitumor effect of in U14 cervical carcinoma-bearing mice. The results showed that GPS + CIS could not only inhibit the growth of the tumor but also improve the spleen and thymus indexes. Moreover, little toxicological effects were observed on hepatic function and renal function in GPS + CIS treated mice bearing U14 tumor cells. Further analysis of the tumor inhibition mechanism indicated that the number of apoptotic tumor cells increased significantly, the expression of Bax increased and the expression of Bcl-2 decreased dramatically in cervical cancer sections after oral administration of GPS + CIS for 14 days. This GPS/CIS combined therapy represents intriguing therapeutic strategy for U14 cervical carcinoma providing not only superior efficacy but also a higher safety level.
迫切需要开展宫颈癌防治研究，以提高临床疗效。顺铂（cisplatin，CIS）作为宫颈癌的主要抗癌药物，已在临床治疗中应用多年。然而，其严重的不良反应，包括肾毒性和神经毒性，限制了其长期治疗。本研究的主要目的是探讨灵芝多糖（Ganoderma lucidum polysaccharides，GPS）对 CIS 诱导的 U14 宫颈癌荷瘤小鼠抗肿瘤作用的改善作用。结果表明，GPS+CIS 不仅能抑制肿瘤生长，还能提高脾和胸腺指数。此外，在 GPS+CIS 治疗 U14 荷瘤小鼠中，肝功能和肾功能未见明显毒理学作用。对肿瘤抑制机制的进一步分析表明，在口服 GPS+CIS 治疗 14 天后，宫颈癌组织中凋亡肿瘤细胞数量明显增加，Bax 表达增加，Bcl-2 表达显著降低。这种 GPS/CIS 联合治疗为 U14 宫颈癌提供了一种有吸引力的治疗策略，不仅疗效更好，而且安全性更高。
